Provided are compounds of Formula (I): ##STR00001##
wherein R.sup.1, R.sup.2, X, Ring A, Ring B, and Ring C are as defined herein. Compounds of Formula (I) are useful as inhibitors of DNA-PK. Also provided are pharmaceutical compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various diseases, conditions, and disorders.

A curable composition containing a compound represented by General Formula A and a salt of an acidic phosphoric acid ester is provided as a curable composition for forming a cured product that has a small Abbe number and a large partial dispersion ratio and has excellent moldability. ##STR00001## In General Formula A, Ar represents an n-valent group containing a nitrogen-containing aromatic ring as a partial structure, L represents a linking group such as O and C(O)O, Sp represents a single bond or a divalent linking group, Pol represents a hydrogen atom or a polymerizable group, and n represents 1 or 2; and the compound represented by General Formula A has at least one polymerizable group.

A curable composition containing a compound represented by General Formula A and a salt of an acidic phosphoric acid ester is provided as a curable composition for forming a cured product that has a small Abbe number and a large partial dispersion ratio and has excellent moldability. ##STR00001## In General Formula A, Ar represents an n-valent group containing a nitrogen-containing aromatic ring as a partial structure, L represents a linking group such as O and C(O)O, Sp represents a single bond or a divalent linking group, Pol represents a hydrogen atom or a polymerizable group, and n represents 1 or 2; and the compound represented by General Formula A has at least one polymerizable group.

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT.sub.2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D.sub.1 and D.sub.2 receptor signaling system, and/or the -opioid receptor.

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT.sub.2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D.sub.1 and D.sub.2 receptor signaling system, and/or the -opioid receptor.